PD-1 inhibitor peptide (Aurigene)

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NamePD-1 inhibitor peptide (Aurigene)
Drug Alias Namepeptide immunomodulator (Aurigene)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsInflammationColonic NeoplasmsCommunicable Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAurigene Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSun Yat-Sen University
Inactive CompaniesAurigene Oncology Ltd
Active IndicationsColonic Neoplasms
Inactive IndicationsInflammationCommunicable Diseases

Other Information

ATC CodeN/A
Related LinksN/A